NEW YORK (GenomeWeb) – T2 Biosystems said today that it has received CE marking for its T2Bacteria Panel, enabling the sale and distribution of the product within the European Union countries and others accepting the mark.

The bacteria panel will be commercially available as part of the T2Sepsis Solution in Europe in the third quarter of 2017, the firm said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.